Reviewing ImmunoGen Inc. (IMGN)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in ImmunoGen Inc. (NASDAQ:IMGN) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 demonstrates ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.

Volatility & Risk

ImmunoGen Inc. has a 2.28 beta, while its volatility is 128.00%, thus making it more volatile than Standard & Poors 500. In other hand, Brainstorm Cell Therapeutics Inc. has beta of 1.19 which is 19.00% more volatile than Standard & Poors 500.

Liquidity

The Current Ratio of ImmunoGen Inc. is 4.7 while its Quick Ratio stands at 4.7. The Current Ratio of rival Brainstorm Cell Therapeutics Inc. is 1 and its Quick Ratio is has 1. ImmunoGen Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc. Recommendations and Ratings are available in the next table.

Brainstorm Cell Therapeutics Inc. on the other hand boasts of a $9 average target price and a 140.64% potential upside.

Insider & Institutional Ownership

Roughly 80.3% of ImmunoGen Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Insiders held roughly 0.6% of ImmunoGen Inc.s shares. On the other hand, insiders held about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year ImmunoGen Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly